Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Baby Friendly Hospital Initiative

 
Introduction:
 
The Baby Friendly Hospital Initiative (BFHI) is a global accreditation program launched in 1991 by the World health organization (WHO) and United Nations International Children's Emergency Fund (UNICEF). 
In Lebanon, the BFHI is led by the Ministry of Public Health (MOPH), particularly the unit of Mother, Child and School health.
 
The BFHI is part of the National Infant and Young Child Feeding (IYCF) policy supported by UNICEF developed in March 2018.
 


The BFHI goal is to improve healthcare for babies, their mothers and families in Lebanon. The BFHI enables health care services to better support mothers and families to ensure that all newborns and infants get the best possible start in life.
 
 
Mission: 
 
The BFHI aims to protect, promote and support breastfeeding practices in healthcare facilities providing maternity and newborn services, while enabling timely and appropriate care and feeding of newborns who are not breastfed.
 
Objectives:

The Six main objectives of the BFHI are to:
  1. Enable mothers to make an informed choice about how to feed their newborns.
  2. Support early initiation of breastfeeding.
  3. Promote exclusive breastfeeding for the first 6 months of life, and introduce nutritionally-adequate and safe complementary (solid) foods at 6 months while continuing breastfeeding up to 2 years of age or beyond.
  4. End distribution of free and low-cost supplies of breast-milk substitutes to maternity wards and hospitals.
  5. Help reduce the levels of infant morbidity and mortality in Lebanon. 
  6. Increase the breastfeeding rates in Lebanon. 
Certification Process:
 
To become a designated Baby Friendly Hospital, hospitals must ensure compliance with the Lebanese law 47/2008 for “organizing the marketing of infant and young child feeding products and tools .
In addition, they should fulfill the requirements of the BFHI 10 steps that have been outlined by the WHO and UNICEF which were reviewed in 2018 and adapted by the Ministry of Public Health in Lebanon.
 
Appendix 1: Law 47/2008
Appendix 2: BFHI 10 steps

The baby friendly hospital (BFH) certification process includes several stages:

First stage:
 
  • Registration: 
The CEO of the hospital working towards baby friendly certification has to fill the BFHI registration form and send it to the unit of Mother, Child and School health at the MOPH via the following e-mail: motherchild@moph.gov.lb
 
Appendix 3: BFHI registration form
     
  • Self-appraisal process:

The hospital undergoes self-appraisal using the WHO self-appraisal tool
This tool is used to evaluate the hospital’s current application and practices of the ten steps to successful breastfeeding. This in turn will help in developing an action plan based on the results of the latter evaluation.
 
Appendix 4: WHO self-appraisal tool
 
  • Orientation visit:
Once the self-appraisal process is completed, an orientation visit to the candidate hospital is performed by the BFHI monitoring team to address the 10 steps criteria requiring additional work for the hospital to become baby friendly.
 
  • Application of commitment: 
The CEO of the hospital or an equivalent hospital staff will fill and sign an application of commitment if the candidate hospital has fulfilled the following requirements:
  • Forming a multidisciplinary breastfeeding committee
  • Assigning a breastfeeding coordinator.
  • Developing a breastfeeding policy that covers all the BFHI steps ( Hospital policy checklist and National Policy sample).
  • Developing the procedures needed for the BFHI 10 steps program.
  • Developing a BFHI work plan to ensure the implementation of 10 steps and the law 47/2008.
  • Developing a training plan for the clinical and non-clinical staff.
  • Developing a prenatal, perinatal and postnatal education plan.
  • Developing a data collection plan for documentation, auditing and evaluation of standards. 
All developed policies, plans and educational materials will be reviewed and approved by The BFHI monitoring team.
 
Appendix 5:  Application of commitment
Appendix 6: WHO policy checklist
Appendix 7: National Policy sample
 
Second stage:
 
  • Implementation stage: 
During this stage the hospital should:
  • Train the clinical staff providing clinical care for pregnant women, mothers and their babies, in addition to training the non-clinical staff providing non-clinical care for pregnant women, mothers and their babies or having contact with them in some aspect of their work.
  • Implement the hospital’s BFHI policy, action plans, and law 47/2008.
  • Collect pertinent data relevant to the 10 steps. Follow up evaluation visits and technical support will be provided by the BFHI monitoring team during the implementation phase.

Appendix 8: Baby Hospital Initiative Implementation Guidance -2018
 
 Third Stage:
 
  • Certification: 
Request for external assessment:
 
Once the evaluation report is completed by the BFHI monitoring team, the CEO of the hospital or an equivalent hospital staff should report to the MOPH (Mother, Child and School health unit) via the following email: motherchild@moph.gov.lb requesting an external assessment.

To note: The report of the national BFHI monitoring team should document the accomplishment of all steps and the hospital documentation and internal audits should be consistent with this report, to facilitate the external auditing process.
 
External assessment:
 
The external assessment is a two-step process:
  1. A verification of the hospital’s policies, educational material, action plans, staff training, and competency verification.
  2. On-site interviews with the staff and patients.
The assessment will be conducted by a certified BFHI assessor, assigned by the IYCF National Committee.
 
Upon successful completion of the required 10 steps by the candidate hospital as reported by the certified BFHI assessor, the hospital will be granted the BFHI certification for 5 years by the MOPH (Mother, Child and School health unit).
 
  • Recertification: 
A redesignation process requires the facility to follow the same steps
 
Appendixes:
Appendix 1: Law 4 /2008
Appendix 2: BFHI 10 steps
Appendix 3: BFHI registration form
Appendix 4: WHO self-appraisal tool
Appendix 5: Application of commitment
Appendix 6: WHO policy checklist
Appendix 7: National Policy sample
Appendix 8: Baby Hospital Initiative Implementation Guidance -2018
 
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
J01FA09 KLACID B Clarithromycin - 125mg/5ml 125mg/5ml Granules for suspension 575,165 L.L
L01XK04 TALZENNA B Talazoparib - 1mg 1mg Capsule 401,512,167 L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet L.L
A06AD65 MOVICOL PEDIATRIC PLAIN B Potassium chloride - 23.3mg, Sodium chloride - 175.4mg, Sodium bicarbonate - 89.3mg, Macrogol 3350 - 6.563g Powder for solution 624,887 L.L
C02AB02 ALDOMET B Methyldopa - 250mg 250mg Tablet, coated 644,400 L.L
C09BB02 ZANIPRESS B Lercanidipine HCl - 10mg, Enalapril maleate - 20mg Tablet, film coated 2,548,821 L.L
G04BD06 MICTONORM B Propiverine HCl - 15mg 15mg Tablet, coated 1,261,868 L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution 2,109,833 L.L
L01XK04 TALZENNA B Talazoparib - 0.25mg 0.25mg Capsule 133,836,699 L.L
M05BA04 FOSAMAX 70MG ONCE WEEKLY B Alendronate - 70mg 70mg Tablet 1,988,887 L.L
S01GA51 NAPHCON A B Naphazoline HCl - 0.025%, Pheniramine maleate - 0.3% Drops solution 369,557 L.L
A10BG03 ACTOS B Pioglitazone HCl - 15mg 15mg Tablet 1,243,054 L.L
C02AB02 ALDOMET B Methyldopa - 500mg 500mg Tablet, coated 856,708 L.L
C09BB02 ZANIPRESS B Lercanidipine HCl - 10mg, Enalapril maleate - 10mg Tablet, film coated 2,280,949 L.L
G04BD06 MICTONORM XL B Propiverine HCl - 30mg 30mg Capsule, modified release 1,648,895 L.L
J01FA09 KLACID B Clarithromycin - 250mg/5ml 250mg/5ml Granules for suspension 1,698,617 L.L
J05AP55 EPCLUSA B Sofosbuvir - 400mg, Velpatasvir - 100mg Tablet, film coated 991,921,769 L.L
L01XK52 AKEEGA B Niraparib - 100mg, Abiraterone acetate - 500mg Tablet, film coated 519,366,124 L.L
N05AX08 RISPERDAL B Risperidone - 4mg 4mg Tablet, film coated 525,442 L.L
N07BC01 BUVIDAL B Buprenorphine - 8mg 8mg Injectable solution prolonged release 8,524,771 L.L
C02AC05 CYNT B Moxonidine - 0.2mg 0.2mg Tablet, film coated 937,444 L.L
C09BB04 COVERAM B Perindopril arginine - 5mg, Amlodipine - 5mg Tablet 821,088 L.L
G04BD06 MICTONORM XL B Propiverine HCl - 45mg 45mg Capsule, modified release 1,877,348 L.L
J05AP56 VOSEVI B Sofosbuvir - 400mg, Velpatasvir - 100mg, Voxilaprevir - 100mg Tablet, film coated 891,634,849 L.L
L01XK52 AKEEGA B Niraparib - 50mg, Abiraterone acetate - 500mg Tablet, film coated 519,366,124 L.L
N05AX08 RISPERDAL B Risperidone - 4mg 4mg Tablet, film coated 525,442 L.L
N07BC01 BUVIDAL B Buprenorphine - 16mg 16mg Injectable solution prolonged release 8,524,771 L.L
R05CA12 PROSPAN ACUTE EFFERVESCENT COUGH TABLETS B Dried Ivy leaf extract - 65mg Tablet, effervescent 479,752 L.L
S01GX02 LEVOPHTA B Levocabastine HCl - 0.5mg/ml 0.05% Suspension 682,672 L.L
A02BB01 CYTOTEC B Misoprostol - 200mcg 200mcg Tablet 737,770 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025